EQRx and Exscientia Enter Strategic Drug Creation, Development, and Commercialization Collaboration to Accelerate the Advancement of New World-Class Medicines
EQRx, a company committed to developing and delivering important new medicines to patients at radically lower prices, and Exscientia, an AI-driven pharmatech company with a mission to radically improve how drugs are discovered, today announced a strategic research and development collaboration agreement. The collaboration will leverage the AI capabilities of Exscientia to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology, further expanding the breadth of EQRx’s pipeline of novel therapies.
This innovative collaboration is focused on creating significant improvements in the traditional drug discovery and development processes by improving the probability of success through each company’s unique capabilities to accelerate the delivery of innovative new medicines—from discovery to commercialization.
Under the terms of the agreement, the strengths of both companies will be leveraged throughout the drug development process. Exscientia will lead the discovery phase through to Investigational New Drug application (IND) filing, while EQRx will be responsible for clinical development, regulatory and commercialization efforts. EQRx and Exscientia will equally share in the discovery, development and commercialization costs.
“Exscientia is a leader in AI-driven drug discovery, and of particular note, has now brought multiple AI-engineered drug candidates to clinical trials. We believe that our aligned focus on efficiency and quality sets a truly unique course to bring the next generation of innovative medicines to patients faster and at a fraction of the cost,” said Alexis Borisy, chairman and chief executive officer of EQRx. “This is a significant step in building EQRx’s robust, sustainable and industry-leading pipeline of important new medicines and substantially accelerates our early-stage research capabilities.”
“We are impatient for patients. EQRx and Exscientia are partners who are equally focused on re-engineering the way we create and distribute drugs for better outcomes for more patients. This exciting new collaboration brings together technologies through a new model that has the potential to truly disrupt how we think about efficiently creating innovative new medicines for all patients,” said Andrew Hopkins, chief executive officer of Exscientia. “Together with the team at EQRx we look forward to building a successful partnership, to enable more patients to access better drugs, faster.”
- MedRhythms Feasibility Study Shows Positive Topline Results in Parkinson’s Disease Read more
- Ionis receives FDA Fast Track designation for Olezarsen in patients with Familial Chylomicronemia Syndrome Read more
- Sensorion and EVEON Collaborating to Develop an Injection System for the Delivery of Gene Therapy Treatments Into the Inner Ear Read more
- Qurient Announces Dosing of First Patient in Clinical Study for the Treatment of Patients with Solid Tumors Read more
- Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors Read more